Opexa shares in meltdown
On Friday Opexa Therapeutics announced that its lead therapy--the MS drug Tovaxin--failed a Phase IIb trial with 150 patients. Researchers said that the therapy demonstrated a positive trend in reducing the annual relapse rate of patients, but said that a higher number of brain lesions in the Tovaxin group skewed the data. Investors, though, fled the stock. Opexa shares lost 92 percent of their value in the afternoon. Opexa release
Comments